Pilot Study on Engaging Family Physicians in Family Planning in Pakistan (FPFP)

December 10, 2022 updated by: Ayaz Ahmed Baloch, Population Council

Assessing the Feasibility, Effectiveness and Outcomes of Engaging Family Physicians and Pharmacies to Expand Family Planning Services in Rural Areas of Islamabad

This study aims to generate evidence on the feasibility and effectiveness of engaging for-profit private sector family physicians and pharmacies to include family planning (FP) as a routine service in rural areas of Pakistan. The study will enlist family physicians and pharmacies in rural areas of Islamabad, Pakistan. Physicians will be randomly assigned to intervention and control groups. Those in intervention arm will received training on family planning and technical support for six months during the duration of the study, to evaluate the impact of training and support in expanding family planning coverage and impact.

Study Overview

Status

Recruiting

Detailed Description

Pakistan has an overall national goal under the National Plan of Action on Population Growth and the national commitment for the international FP2030 goals to expand family planning services by raising Contraceptive Prevalence Rate (CPR) to 60 percent by 2030 in Pakistan . Based on the Population Council's earlier Landscape study of Family planning services, the total market approach has not been fully adopted in Pakistan (The Population Council, 2016). It called for the inclusion of the private sector and pharmacies to expand access to family planning services and commodities. Another study by the Council also explored the potential of including the private sector and proposed the case for engaging family physicians in family planning . The National Plan of Action on Population Growth's recommendation no. 2 calls for engaging the for-profit private sector, especially family physicians in efforts to expand family planning services . However, a review of evidence in 2020 noted that no determined effort was found to engage private physicians to provide family planning in a sustainable and for-profit model. Internationally, the involvement of the private sector in family planning has been proposed as a High Impact Practice (HIP). The ultimate goal of this study is to provide a model for a successful engagement of male family physicians and pharmacies in family planning and, thereby, expanding family planning services in rural areas to achieve universal access to FP. The engagement of for-profit (male) family physicians in the provision of FP services in linkage with pharmacies will combine three high-impact practices (HIPs) in family planning: (i) private sector engagement (ii) male participation in family planning (Khan, K & Sathar, Z, 2020) and (iii) integrating pharmacies in the health system.

This study aims to generate evidence on the feasibility and effectiveness of engaging for-profit private sector family physicians and pharmacies to include family planning (FP) as a routine service. It aims to fill the knowledge gap about the effectiveness of engaging private sector family physicians, and also the optimal approach of integrating family physicians' and pharmacies in Pakistan. Given that the lack of family planning services is particularly dire in rural areas, we situate the study in the rural areas of Islamabad. The study outcomes would provide evidence for advocacy for a sustainable model that can be scaled up to both rural and urban areas.

The study involves an intervention to test the feasibility of engaging male family physicians and pharmacies in expanding the provision of family planning services in the rural areas, on the basis of a review of previous studies, and discussions with a number of private providers, pharmacists, government officials and researchers, The impact of the intervention is to be tested through a randomized control study. The study will enlist family physicians and pharmacies in rural Islamabad Capital Territory (ICT) , who will give their written and informed consent to participate in the study. Physicians will be randomly assigned to intervention and control groups with equal chances of falling into each group.

  • The intervention will provide male family physicians with training and technical support and integrates them with the nearest pharmacies or drug shops for vertical referrals. Technical support will include:
  • Supportive supervision
  • Peer-to-peer support
  • Strengthening referrals for long-acting reversible contraceptives (LARC) and permanent methods
  • Provision of information, education, and communication (IEC) material and LCD for display of visual material.
  • Branding of clinics with signboards
  • Provision of family planning prescription booklets The providers in the intervention group will receive the intervention package, the providers in the control group will continue to provide their services as usual with no exposure to intervention activities. After the end of the intervention period, providers that fall into control areas will be provided the same training. We hypothesize that the proposed intervention will enable male family physicians to provide information, counselling, family planning prescriptions, and referrals, as requested by clients and will result in increased uptake of contraceptive methods.

To evaluate intervention outcomes, baseline assessments in both intervention and control arms will obtain quantitative data from family physicians and pharmacies. We will assess our primary and secondary outcomes using the Management Information System (MIS) tool for obtaining routine service statistics data from clinics and contraceptive sales data from pharmacies. After 6 months of completing the intervention, end-line assessments will be conducted with family physicians in both intervention and control arms to measure changes in providers' KAP towards FP due to intervention. We will also interview family physicians in the intervention arm to get their feedback on the intervention's effectiveness and feasibility through in-depth interviews.

In addition, data on contraceptive availability and sales trends, monitoring stock positions, will be obtained from pharmacies, those nearest to; and linked with participating clinics, at the start, at 3 months, and at 6 months of intervention. The regular availability of contraceptives at the participating pharmacies will be ensured, and mechanisms to address declining stocks or stock outs would be addressed by linking with manufacturers and distributors and with health or population welfare department facilities if needed.

Study Type

Interventional

Enrollment (Anticipated)

76

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

    • Islamabad Capital Territory
      • Islamabad, Islamabad Capital Territory, Pakistan, 44050
        • Recruiting
        • Population Council
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

22 years to 70 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Private clinics with a male family physician
  • Male family physician working on a regular basis (3 or more days a week)
  • Clinics located in Islamabad rural areas.

Exclusion Criteria:

  • Clinics or facilities with specialized care (skin care, laser clinics, surgical clinics, among others)
  • Clinics located in ICT urban areas
  • Male family physicians working in a private clinic where a female medical doctor attends to patients during the same working hours.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Health Services Research
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Intervention Arm

Male Family Physicians allocated to intervention arm will receive following:

Training and technical support and integrates them with the nearest pharmacies or drug shops for vertical referrals.

Technical support will include:

  • Supportive supervision
  • Peer-to-peer support
  • Strengthening referrals for long-acting reversible contraceptives (LARC) and permanent methods
  • Provision of information, education, and communication (IEC) material and LCD for display of visual material.
  • Branding of clinics with name boards
  • Provision of family planning prescription booklets
Same as in Intervention arm description
No Intervention: Control Arm
the providers in the control group will continue to provide their services as usual with no exposure to intervention activities. After the end of the intervention period, providers that fall into control areas will be provided the same training.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Proportion of family physicians successfully providing family planning services to their clients
Time Frame: 6-months
the proportion of family physicians in the intervention arm compared to the control arm providing FP services to at least 10 per cent of their total clients during the intervention period.
6-months

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
change in contraceptive uptake
Time Frame: 6-months
2. Percentage point difference in contraceptive sales in pharmacies linked to clinics in the intervention arm as compared to the control arm.
6-months
change in number of FP clients
Time Frame: 6-months
Estimate the average (mean) number of clients receiving FP services in the intervention group compared to the control group by the end of intervention period.
6-months

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Ayaz Ahmed Baloch, Population Council

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

  • Federal and Provincial Task Force s, 2019, Action Plan (2019-24) for Implementation of Recommendations Approved by CCI Regarding Alarming Population Growth in Pakistan.
  • The Population Council. 2016. Landscape Analysis of Family Planning Situation in Pakistan: Brief Summary of Findings. Islamabad: The Population Council
  • Rehman Ashfaq and Malkani Anam. 2020. Best Bets for Accelerating Family Planning in Pakistan: The Case for Engaging Family Physicians and the for-Profit Private Sector. Islamabad: Population Research Center and the Population Council.
  • Khan, K., & Sathar, Z. (2020). Best Bets for Accelerating Family Planning in Pakistan: Inducting men, sharing responsibility
  • The Population Council. 2019. Improving Access to Family Planning Services through the Private Sector in Pakistan: A Stakeholder Analysis. Islamabad: The Population Council.
  • Bradley, S.E & Shiras, T. Pharmacies and Drug Shops. Expanding contraceptive Choice and access in the private sector. Family Planning High Impact Practices2021

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

November 21, 2022

Primary Completion (Anticipated)

June 30, 2023

Study Completion (Anticipated)

August 30, 2023

Study Registration Dates

First Submitted

December 1, 2022

First Submitted That Met QC Criteria

December 1, 2022

First Posted (Actual)

December 9, 2022

Study Record Updates

Last Update Posted (Estimate)

December 13, 2022

Last Update Submitted That Met QC Criteria

December 10, 2022

Last Verified

December 1, 2022

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

No

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Contraception

Clinical Trials on FP Training and Technical Support

3
Subscribe